The filing is a routine VC distribution notice and does not indicate management concern. However, continued selling by Atlas entities could create near-term overhang. Monitor for further Form 144 filings or Form 4 filings to gauge the pace of distribution.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $116.46entry
- T+1 · 5mo ago −7.16%α −6.44% · $108.12
- T+5 · 5mo ago −2.53%α −3.96% · $113.51
- T+20 · 4mo ago −5.22%α −5.75% · $110.38
- T+60 · 8w ago +1.11%α −2.75% · $117.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Fund X, L.P., a venture capital firm and early investor in Kymera Therapeutics, filed a Form 144 notice of intent to sell 118,178 shares of common stock, valued at approximately $11.6 million. This follows a series of large sales by Atlas entities in June 2026, totaling hundreds of thousands of shares, consistent with a venture fund distributing to limited partners. The proposed sale represents a small fraction (0.12%) of Kymera's $9.4B market cap and is not a signal of fundamental deterioration.
Key Facts
- Atlas Venture Fund X, L.P. filed a Form 144 to sell 118,178 shares of Kymera Therapeutics common stock.
- Estimated market value of the proposed sale is $11,610,988.50.
- Shares were acquired in a private placement on March 11, 2020.
- Atlas entities have sold over 450,000 shares in June 2026 alone, including 243,976 shares on June 22, 2026.
- The selling entity is a venture capital fund, not an executive insider.
Financial Impact
Proposed sale of 118,178 shares (~$11.6M) represents 0.12% of Kymera's $9.4B market cap.
Risk Factors
- Continued selling by Atlas Venture could pressure the stock in the short term.
- Large insider/affiliate sales may be misinterpreted by the market as a negative signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-045290 |
| Document: 0001628280-26-045290-index.html | 0001628280-26-045290 |
| Document: 0001628280-26-045290.txt | 0001628280-26-045290 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers